These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 27659521)

  • 1. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
    Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z
    Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.
    Templeton AJ; Gonzalez LD; Vera-Badillo FE; Tibau A; Goldstein R; Šeruga B; Srikanthan A; Pandiella A; Amir E; Ocana A
    PLoS One; 2016; 11(5):e0154789. PubMed ID: 27149669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis.
    Lee EH; Park SK; Park B; Kim SW; Lee MH; Ahn SH; Son BH; Yoo KY; Kang D; ;
    Breast Cancer Res Treat; 2010 Jul; 122(1):11-25. PubMed ID: 20376556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
    Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    Xu K; Yang S; Zhao Y
    Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
    Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
    Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
    Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
    Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
    Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.